Ana de Barros, PhD, managing science editor —

Ana holds a PhD in immunology from the University of Lisbon and worked as a postdoctoral researcher at Instituto de Medicina Molecular (iMM) in Lisbon, Portugal. Ana was awarded two FCT fellowships and has won the Portuguese Immunology Society Best Paper and Best Poster award in 2009 and 2010, as well as the CESPU International Research Award in 2010. After leaving the lab to pursue a career in science communication, she served as the director of science communication at iMM Lisbon.

Articles by Ana de Barros

Alzheimer’s Disease May Be Caused by Insulin Deficiency

Back in 2005, researchers published findings on Alzheimer’s Disease that were quite bold, linking insulin deficiency with an increased risk for amyloid plaque build up. Amyloid plaque has been associated with this common form of dementia since the early 2000s, and is believed to cause the neurodegenerative…

New Wearable Device May Help Slow Alzheimer’s Progression

Alzheimer’s disease is the most common type of dementia that progressively deteriorates a person’s memory, cognition, and behavior, until accomplishing activities of daily living (ADLs) becomes difficult. Despite decades of intensive research, no one has yet to find a cure for Alzheimer’s. What are currently available are medications…

Alzheimer’s Prevention Registry Enrolls 40,000 Volunteers in Major Research Project

The Alzheimer’s Prevention Registry recently enrolled the 40,000th volunteer to take part in a major study on Alzheimer’s disease that will be conducted by Banner Alzheimer’s Institute (BAI) in collaboration with other organizations and scientists. The online gateway’s main purpose is to accelerate research by connecting healthy people who are committed to…

Stanford Studies Advance Knowledge on Alzheimer’s Functioning

Even though Alzheimer’s disease is typically only diagnosed in the elderly population, the disease is already present in the brain long before symptoms become visible. Researchers at University of Stanford believe they have found a few promising signs that indicate the early presence of the disease in patients as a result of observing the development…

Company Uses Intravenous Stem Cells to Successfully Treat Alzheimer’s

An intravenous administration of allogeneic, human, ischemia-tolerant mesenchymal stem cells (itMSCs) in a pre-clinical animal model of Alzheimer’s disease has been successfully performed by Stemedica International, a subsidiary of Stemedica Cell Technologies, developing stem cell therapies for Alzheimer’s disease and dementia. The first results of the…